What should be continued after fibrinolysis and before transfer in a patient?

In the context of a patient who has undergone fibrinolysis, it is crucial to continue both antiplatelet and anticoagulant therapy before transfer. Fibrinolysis is a treatment aimed at dissolving blood clots, which is often necessary in acute situations such as ST-Elevation Myocardial Infarction (STEMI) or pulmonary embolism.

Continuing antiplatelet therapy helps to prevent new clot formation and reduces the risk of further thrombotic events by inhibiting platelet aggregation. Anticoagulant therapy, on the other hand, is important for maintaining the patency of blood vessels and preventing the re-formation of clots. Both therapies act synergistically to enhance the overall safety and efficacy of the treatment post-fibrinolysis.

Nurse monitoring is always an essential part of patient care but does not provide the preventative benefits of medications in this specific situation. While antiplatelet and anticoagulant therapies are critical in managing the risk of thrombotic complications after fibrinolysis, monitoring alone would not address these risks effectively. Thus, ensuring that both therapies are continued contributes to optimizing patient outcomes before transfer.